(0.33%) 5 116.90 points
(0.30%) 38 354 points
(0.37%) 15 987 points
(-0.87%) $83.12
(5.77%) $2.03
(0.45%) $2 357.80
(0.47%) $27.67
(3.92%) $958.25
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease...
Stats | |
---|---|
本日の出来高 | 12 230.00 |
平均出来高 | 351 183 |
時価総額 | 79.48M |
EPS | $0 ( 2024-03-04 ) |
次の収益日 | ( $-0.370 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.690 |
ATR14 | $0.00700 (0.54%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Borthwick Kathleen | Buy | 227 000 | Employee Stock Option (right to buy) |
2024-03-15 | Forman Mark S | Buy | 203 000 | Employee Stock Option (right to buy) |
2024-03-15 | Chou William | Buy | 575 000 | Employee Stock Option (right to buy) |
2024-03-15 | Cale Edgar B. | Buy | 203 000 | Employee Stock Option (right to buy) |
2024-02-10 | Borthwick Kathleen | Buy | 4 000 | Common Stock |
INSIDER POWER |
---|
82.21 |
Last 96 transactions |
Buy: 8 238 559 | Sell: 441 732 |
ボリューム 相関
Passage Bio Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Passage Bio Inc 相関 - 通貨/商品
Passage Bio Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-3.72M (0.00 %) |
EPS: | $-1.860 |
FY | 2023 |
収益: | $0 |
総利益: | $-3.72M (0.00 %) |
EPS: | $-1.860 |
FY | 2022 |
収益: | $0 |
総利益: | $-3.68M (0.00 %) |
EPS: | $-2.51 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.48 |
Financial Reports:
No articles found.
Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。